Monday, March 31, 2008

Investors flee Merck after Vytorin report in NJEM

See the Forbes report: Vytorin Makes Merck And Schering Swoon.

Things "other than" adverse patent results can affect the price of drug stocks.

0 Comments:

Post a Comment

<< Home